FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2823346501> ?p ?o ?g. }

• W2823346501 endingPage "1842" @default.
• W2823346501 startingPage "1835" @default.
• W2823346501 abstract "The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a deep molecular response (BCR-ABL1IS ≤0.0032%). Successful treatment-free remission was defined as no confirmed loss of deep molecular response. We recruited 96 Japanese patients, of whom 78 sustained a deep molecular response during the consolidation phase and were therefore eligible to discontinue nilotinib in the treatment-free remission phase; of these, 53 patients (67.9%; 95% confidence interval: 56.4–78.1%) remained free from molecular recurrence in the first 12 months. The estimated 3-year treatment-free survival was 62.8%. Nilotinib was readministered to all patients (n=29) who experienced a molecular recurrence during the treatment-free remission phase. After restarting treatment, rapid deep molecular response returned in 25 patients (86.2%), with 50% of patients achieving a deep molecular response within 3.5 months. Tyrosine kinase inhibitor withdrawal syndrome was reported in 11/78 patients during the early treatment-free remission phase. The treatment-free survival curve was significantly better in patients with undetectable molecular residual disease than in patients without (3-year treatment-free survival, 75.6 versus 48.6%, respectively; P=0.0126 by the log-rank test). There were no significant differences in treatment-free survival between subgroups based on tyrosine kinase inhibitor treatment before the nilotinib consolidation phase, tyrosine kinase inhibitor-withdrawal syndrome, or absolute number of natural killer cells. The results of this study indicate that it is safe and feasible to stop tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia who have achieved a sustained deep molecular response with 2 years of treatment with nilotinib. This study was registered with UMIN-CTR (UMIN000005904)." @default.
• W2823346501 created "2018-07-19" @default.
• W2823346501 creator A5004170848 @default.
• W2823346501 creator A5010053494 @default.
• W2823346501 creator A5015013402 @default.
• W2823346501 creator A5015246317 @default.
• W2823346501 creator A5019984630 @default.
• W2823346501 creator A5050827716 @default.
• W2823346501 creator A5052307739 @default.
• W2823346501 creator A5053502496 @default.
• W2823346501 creator A5054154446 @default.
• W2823346501 creator A5056114689 @default.
• W2823346501 creator A5060770246 @default.
• W2823346501 creator A5065276140 @default.
• W2823346501 creator A5068249765 @default.
• W2823346501 creator A5074783271 @default.
• W2823346501 creator A5079175356 @default.
• W2823346501 creator A5082010384 @default.
• W2823346501 creator A5083177745 @default.
• W2823346501 creator A5083314957 @default.
• W2823346501 creator A5087462267 @default.
• W2823346501 creator A5090658715 @default.
• W2823346501 date "2018-07-05" @default.
• W2823346501 modified "2023-10-18" @default.
• W2823346501 title "Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan" @default.
• W2823346501 cites W1827459324 @default.
• W2823346501 cites W1973595070 @default.
• W2823346501 cites W1994501785 @default.
• W2823346501 cites W2061440903 @default.
• W2823346501 cites W2064367288 @default.
• W2823346501 cites W2068470589 @default.
• W2823346501 cites W2072834954 @default.
• W2823346501 cites W2076869962 @default.
• W2823346501 cites W2092782570 @default.
• W2823346501 cites W2117356576 @default.
• W2823346501 cites W2189113171 @default.
• W2823346501 cites W2220816567 @default.
• W2823346501 cites W2260921597 @default.
• W2823346501 cites W2278657325 @default.
• W2823346501 cites W2313607879 @default.
• W2823346501 cites W2345930365 @default.
• W2823346501 cites W2416620684 @default.
• W2823346501 cites W2462710785 @default.
• W2823346501 cites W2528188718 @default.
• W2823346501 cites W2557854027 @default.
• W2823346501 cites W2590307110 @default.
• W2823346501 cites W2733972507 @default.
• W2823346501 cites W2754183140 @default.
• W2823346501 cites W2792384496 @default.
• W2823346501 cites W2799468555 @default.
• W2823346501 cites W2979358778 @default.
• W2823346501 doi "https://doi.org/10.3324/haematol.2018.194894" @default.
• W2823346501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6278957" @default.
• W2823346501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29976734" @default.
• W2823346501 hasPublicationYear "2018" @default.
• W2823346501 type Work @default.
• W2823346501 sameAs 2823346501 @default.
• W2823346501 citedByCount "54" @default.
• W2823346501 countsByYear W28233465012019 @default.
• W2823346501 countsByYear W28233465012020 @default.
• W2823346501 countsByYear W28233465012021 @default.
• W2823346501 countsByYear W28233465012022 @default.
• W2823346501 countsByYear W28233465012023 @default.
• W2823346501 crossrefType "journal-article" @default.
• W2823346501 hasAuthorship W2823346501A5004170848 @default.
• W2823346501 hasAuthorship W2823346501A5010053494 @default.
• W2823346501 hasAuthorship W2823346501A5015013402 @default.
• W2823346501 hasAuthorship W2823346501A5015246317 @default.
• W2823346501 hasAuthorship W2823346501A5019984630 @default.
• W2823346501 hasAuthorship W2823346501A5050827716 @default.
• W2823346501 hasAuthorship W2823346501A5052307739 @default.
• W2823346501 hasAuthorship W2823346501A5053502496 @default.
• W2823346501 hasAuthorship W2823346501A5054154446 @default.
• W2823346501 hasAuthorship W2823346501A5056114689 @default.
• W2823346501 hasAuthorship W2823346501A5060770246 @default.
• W2823346501 hasAuthorship W2823346501A5065276140 @default.
• W2823346501 hasAuthorship W2823346501A5068249765 @default.
• W2823346501 hasAuthorship W2823346501A5074783271 @default.
• W2823346501 hasAuthorship W2823346501A5079175356 @default.
• W2823346501 hasAuthorship W2823346501A5082010384 @default.
• W2823346501 hasAuthorship W2823346501A5083177745 @default.
• W2823346501 hasAuthorship W2823346501A5083314957 @default.
• W2823346501 hasAuthorship W2823346501A5087462267 @default.
• W2823346501 hasAuthorship W2823346501A5090658715 @default.
• W2823346501 hasBestOaLocation W28233465011 @default.
• W2823346501 hasConcept C121608353 @default.
• W2823346501 hasConcept C126322002 @default.
• W2823346501 hasConcept C141071460 @default.
• W2823346501 hasConcept C143998085 @default.
• W2823346501 hasConcept C2776694085 @default.
• W2823346501 hasConcept C2777413986 @default.
• W2823346501 hasConcept C2777583451 @default.
• W2823346501 hasConcept C2778461978 @default.
• W2823346501 hasConcept C2778729363 @default.
• W2823346501 hasConcept C2778820342 @default.
• W2823346501 hasConcept C2779823535 @default.
• W2823346501 hasConcept C2780739268 @default.
• W2823346501 hasConcept C31760486 @default.

• next